Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review
Keywords: 
Materias Investigacion::Ciencias de la Salud
Materias Investigacion::Ciencias de la Salud::Dermatología
CARD14-associated papulosquamous eruption (CAPE)
CARD14
Issue Date: 
2020
Publisher: 
Wiley
ISSN: 
1468-3083
Citation: 
Nieto-Benito, L.M. (Lula M.); Baniandrés-Rodríguez, O. (O.); Moreno, A. (A.); et al. "Clinical response to ustekinumab in CARD14-associated papulosquamous eruption (CAPE) with a new missense mutation in CARD14: a case report and systematic review". Journal of the European Academy of Dermatology and Venereology. 34 (11), 2020, e728 - e730
Abstract
The term CAPE was first introduced by Craiglow et al.1 to define a papulosquamous eruption due to mutations in CARD14 in patients who display characteristics of both psoriasis and pityriasis rubra pilaris (PRP). Heterozygous mutations in CARD14 have been described in psoriasis2 and PRP3, 4 patients, indicating that these disorders share a common underlying pathophysiology.

Files in This Item:
Thumbnail
File
CAPE JEADV.pdf
Description
Size
16.62 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.